Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses.

Bolduc M, Baz M, Laliberté-Gagné MÈ, Carignan D, Garneau C, Russel A, Boivin G, Savard P, Leclerc D.

Nanomedicine. 2018 Nov;14(8):2563-2574. doi: 10.1016/j.nano.2018.08.010. Epub 2018 Sep 5.

PMID:
30193813
2.

A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling.

Thérien A, Bédard M, Carignan D, Rioux G, Gauthier-Landry L, Laliberté-Gagné MÈ, Bolduc M, Savard P, Leclerc D.

J Nanobiotechnology. 2017 Jul 18;15(1):54. doi: 10.1186/s12951-017-0289-y.

3.

Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.

Carignan D, Thérien A, Rioux G, Paquet G, Gagné ML, Bolduc M, Savard P, Leclerc D.

Vaccine. 2015 Dec 16;33(51):7245-7253. doi: 10.1016/j.vaccine.2015.10.123. Epub 2015 Nov 6.

PMID:
26549362
4.

Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.

Tao W, Hurst BL, Shakya AK, Uddin MJ, Ingrole RS, Hernandez-Sanabria M, Arya RP, Bimler L, Paust S, Tarbet EB, Gill HS.

Antiviral Res. 2017 May;141:62-72. doi: 10.1016/j.antiviral.2017.01.021. Epub 2017 Feb 2.

5.

A novel M2e based flu vaccine formulation for dogs.

Leclerc D, Rivest M, Babin C, López-Macias C, Savard P.

PLoS One. 2013 Oct 2;8(10):e77084. doi: 10.1371/journal.pone.0077084. eCollection 2013.

6.

Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).

Mu X, Hu K, Shen M, Kong N, Fu C, Yan W, Wei A.

J Virol Methods. 2016 Feb;228:84-90. doi: 10.1016/j.jviromet.2015.11.014. Epub 2015 Nov 23.

PMID:
26615805
8.

Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.

Wu F, Yuan XY, Huang WS, Chen YH.

Vaccine. 2009 Oct 9;27(43):6095-101. doi: 10.1016/j.vaccine.2008.11.037. Epub 2008 Dec 3.

PMID:
19056447
9.

Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.

Wang W, Li R, Deng Y, Lu N, Chen H, Meng X, Wang W, Wang X, Yan K, Qi X, Zhang X, Xin W, Lu Z, Li X, Bian T, Gao Y, Tan W, Ruan L.

Clin Vaccine Immunol. 2015 Jun;22(6):618-30. doi: 10.1128/CVI.00091-15. Epub 2015 Apr 1.

10.

M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.

Tao W, Gill HS.

Vaccine. 2015 May 11;33(20):2307-15. doi: 10.1016/j.vaccine.2015.03.063. Epub 2015 Apr 2.

11.

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.

Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, Abed Y, Savard C, Pare C, Lopez Macias C, Boivin G, Leclerc D.

Vaccine. 2008 Jun 25;26(27-28):3395-403. doi: 10.1016/j.vaccine.2008.04.052. Epub 2008 May 12.

PMID:
18511159
12.

Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.

Lee YN, Kim MC, Lee YT, Kim YJ, Lee J, Kim C, Ha SH, Kang SM.

Antiviral Res. 2015 Oct;122:82-90. doi: 10.1016/j.antiviral.2015.08.001. Epub 2015 Aug 4.

13.

Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.

Park KS, Seo YB, Lee JY, Im SJ, Seo SH, Song MS, Choi YK, Sung YC.

Vaccine. 2011 Jul 26;29(33):5481-7. doi: 10.1016/j.vaccine.2011.05.062. Epub 2011 Jun 12.

PMID:
21664216
14.

Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP].

Savard C, Laliberté-Gagné MÈ, Babin C, Bolduc M, Guérin A, Drouin K, Forget MA, Majeau N, Lapointe R, Leclerc D.

Vaccine. 2012 Mar 28;30(15):2535-42. doi: 10.1016/j.vaccine.2012.01.085. Epub 2012 Feb 8.

PMID:
22326774
15.

Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.

Staneková Z, Király J, Stropkovská A, Mikušková T, Mucha V, Kostolanský F, Varečková E.

Acta Virol. 2011;55(1):61-7.

PMID:
21434706
16.
17.

[Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].

Stepanova LA, Kovaleva AA, Potapchuk MV, Korotkov AV, Kupriianov VV, Blokhina EA, Kotliarov RIu, Tsybalova LM.

Vopr Virusol. 2013 May-Jun;58(3):21-5. Russian.

PMID:
24006628
18.

Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.

Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L.

Virol J. 2012 Dec 29;9:322. doi: 10.1186/1743-422X-9-322.

19.

Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.

Straight TM, Ottolini MG, Prince GA, Eichelberger MC.

Virol J. 2008 Mar 20;5:44. doi: 10.1186/1743-422X-5-44.

20.

Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles.

Lee YT, Kim KH, Ko EJ, Kim MC, Lee YN, Hwang HS, Lee Y, Jung YJ, Kim YJ, Santos J, Perez DR, Kang SM.

Virology. 2019 Mar;529:111-121. doi: 10.1016/j.virol.2019.01.017. Epub 2019 Jan 15.

PMID:
30685658

Supplemental Content

Support Center